The single therapeutic vaccine, TG4050, developed by French biotech company Transgene, “effectively” stimulates patients’ immune systems, according to phase one results.
Biotech Transgene announced positive results for its single therapeutic cancer vaccine, TG4050, in Phase I trials on Monday.
In a press release, the French company, which is owned by the Meriot Institute, reported data that “demonstrate the great potential of this single immunotherapy against ovarian and head and neck cancers.”
Here the single vaccine aims to target the “most suitable for each patient” cancer cells via a harmless viral vector.
“By the time a patient is diagnosed with cancer, they will of course be cured. […] But at the time of the intervention the tumor recovers and a vaccine can be manufactured in less than three months”, explains Jean-Pierre DeLord, Professor of Oncology at RTL and Director-General of the University Cancer Institute of Toulouse-Encopol where there is one patient. He was treated with this therapeutic vaccine.
A therapeutic project has been developed with the Japanese company NEC, which has developed artificial intelligence that makes it possible to list targeted tumor mutations, also called novel antigens.
Al-Hadi bin Ibrahim indicated last January that “the primary goal is to show that the product has an effect on repelling, and ideally preventing, relapse against cancer.” BFM stock exchangeWhen the trials of head and neck cancer patients began.
Strong cellular response in ovarian cancer patients
Specifically, the first positive data were obtained in the first six treated patients, with four patients with ovarian cancer, having a robust T-cell response against several target mutations. Biotech notes that “no serious adverse effects have been reported in the two studies to date” of the TG4050 vaccine, which is “well tolerated.”
Regarding two patients with head and neck cancer, Transgene notes that they have also been treated with TG4050 “for 10 and 5 months, respectively and are stable.” They continued to receive their treatment.
“Vaccines are the way of the future,” says David Khayat, an oncologist and author of the book. Prevention and treatment of cancer for dummies. “There is no longer any question today about thinking that idea is so far fetched,” he explains Tuesday on our antenna.
French Biotechnology specifies that these two studies are ongoing and will include up to 43 patients residing in France, the United Kingdom and the United States. Who is there to be able to expand this treatment to include all types of cancer? “Almost all, but not all, cancers,” warns Jean-Pierre DeLord, “there are some cancers that do not have enough mutational load and are completely invisible to the immune system, but in all other cases it is likely that a strategy Vaccination is key. The therapeutic era.”
